Search research articles
Contact Us
Filters
Showing results (131-140 of 277) with videos related to
Page
of 28
Sort By:
Oncotarget
|
September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
Vikas Dembla, Neeta Somaiah, Pedro Barata, et al.
Oncotarget
|
July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
Ishwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
Human Pathology
|
February 11, 2014
Molecular characterization of gallbladder cancer using somatic mutation profiling
Milind Javle, Asif Rashid, Chaitanya Churi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
Apostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Investigational New Drugs
|
October 18, 2014
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
Gerald S Falchook, Stacy Moulder, Aung Naing, et al.
JCO Precision Oncology
|
September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated Malignancies
Vivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
The Oncologist
|
August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
Aditya Bardia, Mrinal Gounder, Jordi Rodon, et al.
Gynecologic Oncology Research and Practice
|
May 28, 2016
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
Siqing Fu, Naiyi Shi, Jennifer Wheler, et al.
Molecular Cancer Therapeutics
|
December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Plos One
|
March 4, 2014
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
Denis L Jardim, Jennifer J Wheler, Kenneth Hess, et al.
Page
of 28
Search research articles
Search
Showing results (131-140 of 277) with videos related to
Sort By:
Page
of 28
Oncotarget
|
September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
Vikas Dembla, Neeta Somaiah, Pedro Barata, et al.
Oncotarget
|
July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
Ishwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
Human Pathology
|
February 11, 2014
Molecular characterization of gallbladder cancer using somatic mutation profiling
Milind Javle, Asif Rashid, Chaitanya Churi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
Apostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Investigational New Drugs
|
October 18, 2014
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
Gerald S Falchook, Stacy Moulder, Aung Naing, et al.
JCO Precision Oncology
|
September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated Malignancies
Vivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
The Oncologist
|
August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
Aditya Bardia, Mrinal Gounder, Jordi Rodon, et al.
Gynecologic Oncology Research and Practice
|
May 28, 2016
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
Siqing Fu, Naiyi Shi, Jennifer Wheler, et al.
Molecular Cancer Therapeutics
|
December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Plos One
|
March 4, 2014
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
Denis L Jardim, Jennifer J Wheler, Kenneth Hess, et al.
Page
of 28